Institute of Biomedical Research Corp. (MRES) Stock

About Institute of Biomedical Research Corp.

Institute of Biomedical Research Corp. (MRES) is a dedicated provider of comprehensive biomedical research and analytical services, operating both within Montenegro and across international markets. The company's core activities encompass fundamental scientific investigation and robust research and development initiatives for new biomedical products, advanced technologies, and innovative diagnostic methods, including experimental medical treatments. MRES also focuses on the creation of novel biomedical and food products. A significant part of its mandate involves regulatory oversight of industrial activities and their associated products, alongside scientific environmental monitoring. Furthermore, it delivers expert regulatory evaluation and certification services for a wide array of biomedical products. The institute also contributes to academic advancement through graduate research study programs in the biomedical and environmental fields. MRES manufactures and supplies a diverse range of healthcare devices. Its offerings include two-channel analog NMS units, various digital muscle stimulators, digital TENS devices, interferential therapy units, elite combination models, portable four-channel digital stimulators, and portable ultrasound equipment. The product portfolio also extends to photon red light devices for aesthetic applications, electric pain relief solutions, microcurrent electrical nerve stimulators, and high-volt pulsed stimulators. The company excels in the development and commercialization of specialized agents and products. This category features microbicidal agents, a variety of disinfectant solutions, and specialized medical supplies such as bandages tailored for severe burns. They also provide products for hard surface disinfection, microbicidal treatments for fabrics and textiles, insecticides (including those targeting bed bugs), microbicidal towels, and mouthwash. Key innovations include Purilair, an apparatus specifically designed for sterilizing compressed air within medical instruments, alongside colloidal silver and other electro-medical devices. A notable product is BioStim INF, which is engineered for reducing edema, alleviating pain, and delivering comprehensive therapeutic benefits. Beyond its product and research endeavors, MRES offers a broad spectrum of essential services. These include quality control, regulatory assistance, healthcare support, environmental analysis, building decontamination, and extensive environmental protection and management services. They are also a critical source for regulatory certifications of new biomedical products. Institute of Biomedical Research Corp. was established in 2010 and maintains its headquarters in Podgorica, Montenegro, with a representative office located in Montreal, Canada, facilitating its global operations.

Institute of Biomedical Research Corp. (MRES) stock trades at $0.00 with a market capitalization of $3.30M. The stock is valued at a price-to-earnings (P/E) ratio of 1.50, price-to-book of -5.98, price-to-sales of 119.08. Over the past 52 weeks the stock has ranged between $0.00 and $0.02, and currently trades 100.0% below its 52-week high.

On profitability, Institute of Biomedical Research Corp. generates a return on equity (ROE) of 200.00% — well above the market average, a sign of a high-quality business, return on capital employed of 61.79%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: mrescorp.com